NCT04973163 - A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 9, 2021

Primary Completion Date

November 29, 2025

Study Completion Date

December 27, 2025

Conditions

Solid Tumors, KRAS Mutation

Interventions

DRUG

BI 1823911

DRUG

BI 1701963

DRUG

Midazolam

Midazolam - only administered in Part B (dose confirmation) of the Monotherapy Arm

Trial Locations (8)

Brussels - HOSP Jules Bordet, Anderlecht/Brussels-Capital

Edegem - UNIV UZ Antwerpen, Edegem/Antwerpen

UZ Leuven, Leuven/Vlaams-Brabant

UNIV UZ Gent, Gent/Oost-Vlaanderen

Mary Crowley Cancer Research Center, Dallas

The University of Texas MD Anderson Cancer Center, Houston

Hospital Vall d'Hebron, Barcelona

The Christie, Manchester